JP7685314B2 - ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法 - Google Patents

ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法 Download PDF

Info

Publication number
JP7685314B2
JP7685314B2 JP2019562655A JP2019562655A JP7685314B2 JP 7685314 B2 JP7685314 B2 JP 7685314B2 JP 2019562655 A JP2019562655 A JP 2019562655A JP 2019562655 A JP2019562655 A JP 2019562655A JP 7685314 B2 JP7685314 B2 JP 7685314B2
Authority
JP
Japan
Prior art keywords
bbr
udca
berberine
ursodeoxycholic acid
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519654A5 (enExample
JP2020519654A (ja
Inventor
ユ，メン
リュウ，リーピン
フ，シンシャン
Original Assignee
シェンツェン ハイタイド バイオファーマシューティカル エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェンツェン ハイタイド バイオファーマシューティカル エルティーディー． filed Critical シェンツェン ハイタイド バイオファーマシューティカル エルティーディー．
Publication of JP2020519654A publication Critical patent/JP2020519654A/ja
Publication of JP2020519654A5 publication Critical patent/JP2020519654A5/ja
Priority to JP2023020228A priority Critical patent/JP7728295B2/ja
Application granted granted Critical
Publication of JP7685314B2 publication Critical patent/JP7685314B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019562655A 2017-05-12 2018-05-11 ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法 Active JP7685314B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023020228A JP7728295B2 (ja) 2017-05-12 2023-02-13 ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710335467.5A CN108864077B (zh) 2017-05-12 2017-05-12 小檗碱有机酸盐的固体形式及其制备方法
CN201710335467.5 2017-05-12
PCT/CN2018/086461 WO2018205987A1 (en) 2017-05-12 2018-05-11 Solid forms of berberine ursodeoxycholate and compositions and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020228A Division JP7728295B2 (ja) 2017-05-12 2023-02-13 ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法

Publications (3)

Publication Number Publication Date
JP2020519654A JP2020519654A (ja) 2020-07-02
JP2020519654A5 JP2020519654A5 (enExample) 2021-07-26
JP7685314B2 true JP7685314B2 (ja) 2025-05-29

Family

ID=64105207

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019562655A Active JP7685314B2 (ja) 2017-05-12 2018-05-11 ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
JP2023020228A Active JP7728295B2 (ja) 2017-05-12 2023-02-13 ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023020228A Active JP7728295B2 (ja) 2017-05-12 2023-02-13 ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法

Country Status (10)

Country Link
US (3) US10959999B2 (enExample)
EP (2) EP3625229B9 (enExample)
JP (2) JP7685314B2 (enExample)
KR (2) KR20250017765A (enExample)
CN (1) CN108864077B (enExample)
AU (2) AU2018264384B2 (enExample)
CA (1) CA3062833A1 (enExample)
EA (1) EA201992607A1 (enExample)
ES (1) ES2988672T3 (enExample)
WO (1) WO2018205987A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864077B (zh) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
CN110954645B (zh) * 2019-09-09 2020-09-29 山东琪康生物技术有限公司 一种高质量四黄止痢颗粒的检测方法
CN112851660B (zh) * 2019-11-12 2022-03-18 广东药科大学 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途
KR102636847B1 (ko) * 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
CN111920777A (zh) * 2020-09-18 2020-11-13 四川迪菲特药业有限公司 一种盐酸小檗碱片及其制备方法
EP4232045A4 (en) * 2020-10-23 2024-09-04 Shenzhen Hightide Biopharmaceutical Ltd. BERBERINE URSODEOXYCHOLATE COMPOSITIONS AND RELATED METHODS FOR THE TREATMENT OF FATTY LIVER, DIABETES AND HYPERLIPIDEMIA
US20230112845A1 (en) * 2020-10-23 2023-04-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia
US20230346803A1 (en) * 2021-01-28 2023-11-02 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis
WO2022161468A1 (en) * 2021-01-28 2022-08-04 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis
WO2023088463A1 (en) * 2021-11-22 2023-05-25 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions
CN114716498B (zh) * 2022-01-20 2024-01-23 成都贝诺科成生物科技有限公司 一种高稳定性的失碳熊去氧胆酸小檗碱盐晶型及其制备方法
CN115477647A (zh) * 2022-10-26 2022-12-16 山西医科大学 小檗碱富马酸盐晶型及其制备方法和其组合物与应用
WO2024120452A1 (en) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for prophylaxis and treatment of covid-19
EP4642454A1 (en) * 2022-12-30 2025-11-05 Shenzhen Hightide Biopharmaceutical Ltd. Pharmaceutical combinations and compositions, and methods of use thereof
CN120659782A (zh) * 2023-02-15 2025-09-16 深圳君圣泰生物技术有限公司 小檗碱牛磺熊去氧胆酸盐组合物及其方法
WO2024179570A1 (en) * 2023-03-01 2024-09-06 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating severe hypertriglyceridemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693805A (zh) 2016-03-15 2016-06-22 合肥华方医药科技有限公司 一种胆酸类小檗碱偶合物的制备及医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005644A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
US20070032555A1 (en) 2005-07-01 2007-02-08 Concert Pharmaceuticals Inc. Novel aryloxyphenyl-propanamines
KR20080047375A (ko) 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. 약제 화합물
AU2006275595B2 (en) 2005-07-29 2012-08-16 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives
CN102229636A (zh) * 2011-04-21 2011-11-02 东北林业大学 小檗碱9位酯键偶合胆酸的新衍生物及其制备方法
US9597337B2 (en) * 2014-04-04 2017-03-21 North American Biomedical Research Center Usa, Inc. Berberine-ursodeoxycholic acid conjugate for treating the liver
CN110179792A (zh) 2014-07-29 2019-08-30 深圳君圣泰生物技术有限公司 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用
CN108864077B (zh) * 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693805A (zh) 2016-03-15 2016-06-22 合肥华方医药科技有限公司 一种胆酸类小檗碱偶合物的制备及医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Patrick AUGUSTIJNS、et al.、Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics、米国、Springer、2007年、pp. 53-109
松岡 正邦監修、結晶多形の基礎と応用、株式会社 シーエムシー出版、２０１０年１０月２２日、普及版 第１刷発行、第１０５～１１７頁、第１８１～１９１頁

Also Published As

Publication number Publication date
JP2023104925A (ja) 2023-07-28
CN108864077A (zh) 2018-11-23
KR20230017930A (ko) 2023-02-07
JP7728295B2 (ja) 2025-08-22
KR102761338B1 (ko) 2025-02-04
EP3625229B1 (en) 2024-07-31
JP2020519654A (ja) 2020-07-02
EA201992607A1 (ru) 2020-06-29
US20210251981A1 (en) 2021-08-19
US20250099456A1 (en) 2025-03-27
US12138258B2 (en) 2024-11-12
NZ759154A (en) 2024-07-26
AU2018264384B2 (en) 2022-05-19
EP3625229C0 (en) 2024-07-31
EP4234568A2 (en) 2023-08-30
AU2022206685B2 (en) 2024-05-02
US10959999B2 (en) 2021-03-30
KR20250017765A (ko) 2025-02-04
EP3625229B9 (en) 2024-10-09
EP4234568A3 (en) 2024-01-03
US20200188387A1 (en) 2020-06-18
EP3625229A1 (en) 2020-03-25
CN108864077B (zh) 2020-05-22
EP3625229A4 (en) 2021-03-03
AU2022206685A1 (en) 2022-08-11
WO2018205987A1 (en) 2018-11-15
ES2988672T3 (es) 2024-11-21
CA3062833A1 (en) 2018-11-15
AU2018264384A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP7728295B2 (ja) ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
TWI874490B (zh) 三苯化合物之新穎鹽類
JP2024105460A (ja) ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態
JP6649511B2 (ja) タファミジスメグルミン塩の結晶形ｅ及びその製造方法並びに用途
JP2024150466A (ja) Ｌｎｐ０２３の結晶形態
JP2023553930A (ja) トレブルチニブの結晶形態、その製造方法、およびその使用
JP2024520897A (ja) ヘモグロビン調節因子の固体形態
JP2025183212A (ja) ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
JP2019500385A (ja) モルホリン誘導体の塩、結晶形、その製造方法、これらを含む医薬組成物およびその用途
EP3830091A1 (en) Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
HK40092147A (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
KR20230061431A (ko) 아데노신 a2b 수용체 길항제의 공결정
EP2588444A1 (en) New polymorphic form of a calcimimetic compound
CN114478679A (zh) 双氢青蒿素-熊去氧胆酸缀合物的多晶型物及其制备方法和应用
JP7603328B2 (ja) １，２，４－オキサジアゾール誘導体の固体製剤
EA041133B1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
KR20250107281A (ko) 아세틸콜린에스테라제 억제제의 결정형 및 이의 제조 방법과 응용
EP3412661A1 (en) Cocrystals of vortioxetine hydrobromide and resorcinol
TW202541790A (zh) 馬立馬司他之結晶多晶型、馬立馬司他之非晶質型、其製備的製程、包含其之藥物組成物及其用途
JP2025539918A (ja) Ｎ－置換フェニルスルホンアミド系化合物の固体形態
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
HK40074169A (en) Solid formulation of a 1,2,4-oxadiazole derivative
HK40074169B (en) Solid formulation of a 1,2,4-oxadiazole derivative
PT2300473E (pt) Sal de fumarato de 1,4-diazabiciclo[3.2.2]nonano-4-carboxilato de 4-bromofenilo, suas formas cristalinas, sua preparação e sua utilização em terapia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210505

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210505

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230213

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230419

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230511

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250519

R150 Certificate of patent or registration of utility model

Ref document number: 7685314

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150